These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 26605043)
1. Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy. Jumpertz von Schwartzenberg R; Elbelt U; Ventz M; Mai K; Kienitz T; Maurer L; Rose T; Rückert JC; Strasburger CJ; Spranger J Endocrinol Diabetes Metab Case Rep; 2015; 2015():150082. PubMed ID: 26605043 [TBL] [Abstract][Full Text] [Related]
2. Control of Refractory Hypercalcemia with Denosumab in a Case of Metastatic Parathyroid Carcinoma. Çalapkulu M; Gul OO; Cander S; Ersoy C; Erturk E; Sagiroglu MF; Saraydaroglu O J Coll Physicians Surg Pak; 2020 Jul; 30(7):757-759. PubMed ID: 32811610 [TBL] [Abstract][Full Text] [Related]
3. Denosumab for management of parathyroid carcinoma-mediated hypercalcemia. Vellanki P; Lange K; Elaraj D; Kopp PA; El Muayed M J Clin Endocrinol Metab; 2014 Feb; 99(2):387-90. PubMed ID: 24178790 [TBL] [Abstract][Full Text] [Related]
4. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia. Fountas A; Andrikoula M; Giotaki Z; Limniati C; Tsakiridou E; Tigas S; Tsatsoulis A Endocr Pract; 2015 May; 21(5):468-73. PubMed ID: 25667369 [TBL] [Abstract][Full Text] [Related]
5. Denosumab for the Treatment of Hypercalcemia in a Patient With Parathyroid Carcinoma: A Case Report. Roukain A; Alwan H; Bongiovanni M; Sykiotis GP; Kopp PA Front Endocrinol (Lausanne); 2021; 12():794988. PubMed ID: 35173680 [TBL] [Abstract][Full Text] [Related]
6. Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment. Tzotzas T; Goropoulos A; Karras S; Terzaki A; Siolos A; Doumas A; Zaramboukas T; Tigas S Hormones (Athens); 2022 Mar; 21(1):171-176. PubMed ID: 34993886 [TBL] [Abstract][Full Text] [Related]
7. Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab. Karuppiah D; Thanabalasingham G; Shine B; Wang LM; Sadler GP; Karavitaki N; Grossman AB Eur J Endocrinol; 2014 Jul; 171(1):K1-5. PubMed ID: 24743399 [TBL] [Abstract][Full Text] [Related]
8. Denosumab treatment for refractory hypercalcemia in a hemodialysis patient with tertiary hyperparathyroidism. Zhang P; Yu Y; Gao Y; Yuan G; Zhang J; Wang W Hemodial Int; 2023 Apr; 27(2):E23-E28. PubMed ID: 36719850 [TBL] [Abstract][Full Text] [Related]
9. Successful Use of Denosumab for Life-Threatening Hypercalcemia in a Pediatric Patient with Primary Hyperparathyroidism. Mamedova E; Kolodkina A; Vasilyev EV; Petrov V; Belaya Z; Tiulpakov A Horm Res Paediatr; 2020; 93(4):272-278. PubMed ID: 32998142 [TBL] [Abstract][Full Text] [Related]
10. Denosumab for management of severe hypercalcemia in primary hyperparathyroidism. Eremkina A; Krupinova J; Dobreva E; Gorbacheva A; Bibik E; Samsonova M; Ajnetdinova A; Mokrysheva N Endocr Connect; 2020 Oct; 9(10):1019-1027. PubMed ID: 33112830 [TBL] [Abstract][Full Text] [Related]
11. Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma. Ashihara N; Nakajima K; Nakamura Y; Kobayashi M; Shirahata K; Maeda C; Uehara T; Gomi D; Ito N Intern Med; 2016; 55(23):3453-3457. PubMed ID: 27904108 [TBL] [Abstract][Full Text] [Related]
12. Successful Control of Hypercalcemia with Sorafenib, Evocalcet, and Denosumab Combination Therapy for Recurrent Parathyroid Carcinoma. Makino H; Notsu M; Asayama I; Otani H; Morita M; Yamamoto M; Yamauchi M; Nakao M; Miyake H; Araki A; Uchino S; Kanasaki K Intern Med; 2022 Nov; 61(22):3383-3390. PubMed ID: 35370235 [TBL] [Abstract][Full Text] [Related]
13. Humoral Hypercalcemia in a Patient with Cholangiocellular Carcinoma - Effective Therapy with Denosumab. Harsch IA; Konturek PC Am J Case Rep; 2019 Sep; 20():1325-1330. PubMed ID: 31492829 [TBL] [Abstract][Full Text] [Related]
14. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism. Jansson S; Tisell LE; Lindstedt G; Lundberg PA Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370 [TBL] [Abstract][Full Text] [Related]
15. Use of denosumab to treat refractory hypercalcemia in a peritoneal dialysis patient with immobilization and tertiary hyperparathyroidism. Pratt RM; West ML; Tennankore KK Perit Dial Int; 2020 Jan; 40(1):103-106. PubMed ID: 32063140 [TBL] [Abstract][Full Text] [Related]
16. Denosumab Therapy for Refractory Hypercalcemia Secondary to Squamous Cell Carcinoma of Skin in Epidermolysis Bullosa. Giri D; Ramakrishnan R; Hayden J; Brook L; Das U; Mughal MZ; Selby P; Dharmaraj P; Senniappan S World J Oncol; 2015 Apr; 6(2):345-348. PubMed ID: 29147430 [TBL] [Abstract][Full Text] [Related]
17. Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis. Akinci B; Comlekci A; Tankurt E Exp Clin Endocrinol Diabetes; 2009 Mar; 117(3):142-5. PubMed ID: 18561096 [TBL] [Abstract][Full Text] [Related]
18. Long-Term Use of Cinacalcet in Kidney Transplant Recipients With Hypercalcemic Secondary Hyperparathyroidism: A Single-Center Prospective Study. Zavvos V; Fyssa L; Papasotiriou M; Papachristou E; Ntrinias T; Savvidaki E; Goumenos DS Exp Clin Transplant; 2018 Jun; 16(3):287-293. PubMed ID: 29108515 [TBL] [Abstract][Full Text] [Related]
19. Hypercalcemia after discontinuation of long-term denosumab treatment. Koldkjær Sølling AS; Harsløf T; Kaal A; Rejnmark L; Langdahl B Osteoporos Int; 2016 Jul; 27(7):2383-2386. PubMed ID: 27098536 [TBL] [Abstract][Full Text] [Related]
20. Hypercalcemia of malignancy treated with cinacalcet. Asonitis N; Kassi E; Kokkinos M; Giovanopoulos I; Petychaki F; Gogas H Endocrinol Diabetes Metab Case Rep; 2017; 2017():. PubMed ID: 29399364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]